Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Cytotherapy. 2014 May 20;16(11):1453–1466. doi: 10.1016/j.jcyt.2014.03.009

Table 3.

Trials of Adoptive NK cell therapy

Disease Setting Method of preparation Cell number Concomitant medication n Effect on patient outcome
AML NK-DLI for patients in first CR following chemotherapy Apheresis followed by CD3 depletion and subsequent CD56 selection 2.9 × 107/kg (range 0.5–8 × 107/kg) Cyclophosphamide (day −7)
Fludarabine (Day −6 to −2)
10 100% 2 year event free survival NKAML study (80)
AML NK-DLI for poor prognosis AML Apheresis followed by CD3 depletion and ex-vivo stimulation with IL2 1 ×105 – 2 ×107 Low dose cyclophosphamide/melphalan vs. High dose cyclophosphamide and fludarabine.
IL2 given to all patients
19 Complete haematological remission in 5 of 19 patients (42)
Myeloma Haploidentical KIR ligand mismatched NK- DLI followed by delayed autologous stem cell transplant Apheresis followed by CD3 depletion 2.4×107/kg Melphalan and fludarabine conditioning 10 Near CR in 50% of patients (81)
CD20+ NHL NK-DLI for refractory disease (more than 2 salvage therapies) Apheresis followed by CD3 depletion 2.1 × 107/kg (range 0.2–40 × 107/kg) Fludarabine (25mg/m2)
Cyclophosphamide (60mg/m2)
6 4 objective remissions
2 complete remissions
(83)
Not stated Allogeneic stem cell transplant Apheresis followed by CD3 depletion and subsequent CD56 selection 1.2×107/kg Not stated 14 NK infusions well tolerated, aside one case of grade IV (131)
High risk myeloid malignancies Graft failure/mixed donor chimerism following allogeneic (haploidentical) stem cell transplant Apheresis followed by CD3 depletion and subsequent CD56 selection 1.61 × 107/kg (range 0.21–2.2) None 5 Reversal of mixed donor chimerism in 2/5 (132)
Not stated Following 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic transplant Apheresis followed by CD3 depletion and CD56 selection 1.06 × 107/kg Infusion performed 6–8 weeks following fludarabine conditioned allogeneic transplant with alemtuzumab 30 Improved T cell recovery and duration of remission (133)
Breast and ovarian carcinoma NK DLI for patients with relapsed disease Apheresis followed by CD3 depletion 2.17 × 107/kg Fludarabine and cyclophosphamide
Total body irradiation in 7 patients
IL2 x6 doses s.c. post DLI
20 TBI improved longevity of NK engraftment (134)
Colorectal carcinoma, hepatocellular carcinoma, renal cell carcinoma and B-CLL Previous allogeneic BMT with donor derived NK cells Apheresis followed by ex vivo expansion with IL-2 0.1 × 107 followed by two doses mean 3.3 × 107 Variable; some patients received sc IL-2 5 Minor responses in 2 patients (135)
Advanced non-small cell lung cancer NK-DLI after chemotherapy CD56 selection followed by culture with IL-15 0.46 × 107/kg (range 0.2–2.9) 2–4 doses of NK DLIs given 2 days after chemotherapy (carboplatin-paclitaxel most commonly used) 16 Trend to better OS in subgroup receiving 4 doses of NK cells (136)
Advanced renal cell carcinoma and malignant melanoma NK-92 cell line infusion Expansion of NK lymphoma cell line Up to 3 × 109/m2 Cell infusion alone 12 Infusion well tolerated. Possible response in 2 patients (86)